share_log

HC Wainwright & Co.:重申Arcutis Biotherapeutics评级

Stock Star ·  Jan 13 12:02

HC Wainwright&Co.:重申arcutis Biotherapeutics(ARQT.US)评级,由买入调整至买入评级,目标价由19.00美元调整至19.00美元。

Arcutis Biotherapeutics(ARQT.US)公司简介:Arcutis Biotherapeutics Inc是一家医学皮肤科公司。它正在为患有免疫介导的皮肤病和病症的患者开发治疗方法。它利用免疫学和炎症方面的最新进展,开发针对经生物学验证的目标的差异化疗法,以解决严重皮肤疾病中持续存在的治疗挑战。该公司的主要候选产品ZORYVE roflumilast乳膏已成功完成斑块状银屑病的关键3期临床试验,证明该人群的症状得到改善且耐受性良好。

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 231

Recommended

Write a comment

Statement

This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.